Peel Hunt restated their buy rating on shares of Oxford BioMedica (LON:OXB) in a research note issued to investors on Thursday.
Separately, Jefferies Financial Group downgraded shares of Oxford BioMedica to a hold rating in a report on Wednesday, June 13th.
Shares of Oxford BioMedica stock opened at GBX 924 ($12.04) on Thursday. Oxford BioMedica has a fifty-two week low of GBX 4.44 ($0.06) and a fifty-two week high of GBX 13.19 ($0.17).
In related news, insider Lorenzo Tallarigo purchased 306 shares of the firm’s stock in a transaction on Monday, July 23rd. The shares were acquired at an average price of GBX 867 ($11.29) per share, for a total transaction of £2,653.02 ($3,455.80). Also, insider John Dawson sold 10,046 shares of the business’s stock in a transaction on Tuesday, August 7th. The stock was sold at an average price of GBX 890 ($11.59), for a total transaction of £89,409.40 ($116,463.98). Insiders purchased a total of 870 shares of company stock valued at $798,342 in the last ninety days.
About Oxford BioMedica
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.
See Also: What is a Fiduciary?
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.